Metabolic bone disease following organ transplantation

Abstract

Solid organ transplantation offers a valuable therapeutic option to patientswith terminal organ failure. Over the years, technical and therapeutic progress, especially the advent of new immunosuppressive agents, has signifi cantly improved outcomes. The survival rate, for example, of a kidney transplant recipient at 1-year today exceeds 95 % [1]. Graft half-life has also increased dramatically almost to 10 years [2]. As transplant recipients live longer, patients and health care providers alike have become increasingly aware of complications related to transplantation.